Dietary flaxseed interaction with tamoxifen induced tumor regression in athymic mice with MCF-7 xenografts by downregulating the expression of estrogen related gene products and signal transduction pathways

Nutrition and Cancer

Volumn 58, Issue 2, 2007, Pages 162-170

  Chen, Jianmin ^a   Power, Krista A ^a   Mann, Jaskaren ^a   Cheng, Astor ^a   Thompson, Lilian U ^a  

^a UNIVERSITY OF TORONTO   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLIN D1; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN; ESTROGEN RECEPTOR; GENE PRODUCT; SOMATOMEDIN C RECEPTOR; TAMOXIFEN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CELL GROWTH; CELL PROLIFERATION; CONTROLLED STUDY; DIETARY INTAKE; DOWN REGULATION; DRUG FORMULATION; DRUG MECHANISM; FOOD DRUG INTERACTION; GENE EXPRESSION; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; LINSEED; MOUSE; NONHUMAN; SIGNAL TRANSDUCTION; TUMOR REGRESSION; XENOGRAFT;

MUS;

EID: 34548252876     PISSN: 01635581     EISSN: None     Source Type: Journal    
DOI: 10.1080/01635580701328271     Document Type: Article

References (54)

1. Thompson LU: Flaxseed, lignans, and cancer. In Flaxseed in Human Nutrition (2nd ed.), Thompson LU and Cunnane SC (eds.). Champaign, IL: AOCS Press, 2003, pp. 194-222.
2. Thompson LU, Seidl MM, Richard SE, Orcheson LJ, and Fong HH: Antitumorigenic effect of a mammalian lignan precursor from flaxseed. Nutr Cancer 26, 159-165, 1996.
3. Bougnoux P and Chajes V: α-Linolenic acid and cancer. In Flaxseed in Human Nutrition (2nd ed.), Thompson LU and Cunnane SC (eds.). Champaign, IL: AOCS Press, 2003, pp. 232-244.
4. Serraino M and Thompson LU: The effect of flaxseed supplementation on early risk markers for mammary carcinogenesis. Cancer Lett 60, 135-142, 1991.
5. Thompson LU, Rickard SE, Orcheson LJ, and Seidl MM: Flaxseed and its lignan and oil components reduce mammary tumor growth at a late stage of carcinogenesis. Carcinogenesis 17, 1373-1376, 1996.
6. Rickard SE, Yuan YV, Chen J, and Thompson LU: Dose effects of flaxseed and its lignan on N-methyl-N-nitrosourea-induced mammary tumorigenesis in rats. Nutr Cancer 35, 50-57, 1999.
7. Chen J, Stavro PM, and Thompson LU: Dietary flaxseed inhibits human breast cancer growth and metastasis and downregulates expression of insulin-like growth factor and epidermal growth factor receptor. Nutr Cancer 43, 187-192, 2002.
8. Dabrosin C, Chen J, Wang L, and Thompson LU: Flaxseed inhibits metastasis and decreases extracellular vascular endothelial growth factor in human breast cancer xenografts. Cancer Lett 185, 31-37, 2002.
9. Chen J, Wang L, and Thompson LU: Flaxseed and its components reduce metastasis after surgical excision of solid human breast tumor in nude mice. Cancer Lett 234, 168-175, 2006.
10. Wang L, Chen J, and Thompson LU: The inhibitory effect of flaxseed on the growth and metastasis of estrogen receptor negative human breast cancer xenografts is attributed to both its lignan and oil components. Int J Cancer 116, 793-798, 2005.
11. Thompson LU, Chen JM, Li T, Strasser-Weippl K, and Goss PE: Dietary flaxseed alters tumor biological markers in postmenopausal breast cancer. Clin Cancer Res 11, 3828-3835, 2005.
12. Furr BJ and Jordan VC: The pharmacology and clinical uses of tamoxifen. Pharmacol Ther 25, 127-205, 1984.
13. Jordan VC: The past, present, and future of selective estrogen receptor modulation. Ann N Y Acad Sci 949, 72-79, 2001.
14. MacGregor JI and Jordan VC: Basic guide to the mechanisms of antiestrogen action. Pharmacol Rev 50, 151-196, 1998.
15. Duffy C and Cyr M: Phytoestrogens: potential benefits and implications for breast cancer survivors. J Womens Health 12, 617-631, 2003.
16. Chen J, Hui E, Ip T, and Thompson LU: Dietary flaxseed enhances the inhibitory effect of tamoxifen on the growth of estrogen-dependent human breast cancer (mcf-7) in nude mice. Clin Cancer Res 10, 7703-7711, 2004.
17. Santen RJ: Long-term tamoxifen therapy: can an antagonist become an agonist? J Clin Endocrinol Metab 81, 2027-2029, 1996.
18. Ring A and Dowsett M: Mechanisms of tamoxifen resistance. Endocr Relat Cancer 11, 643-658, 2004.
19. Olfer ED, Cross BM, and Mc William AA (eds.): The Guide to the Care and Use of Experimental Animals (Vol. 1, 2nd ed.). Ottawa, Ontario, Canada: Canadian Council on Animal Care, 1993.
20. Reeves PG, Nielsen FH, and Fahey Jr. GC: AIN-93 purified diets for laboratory rodents: final report of the American Institute of Nutrition ad hoc writing committee on the reformulation of the AIN-76A rodent diet. J Nutr 123, 1939-1951, 1993.
21. Ju YH, Doerge DR, Allred KF, Allred CD, and Helferich WG: Dietary genistein negates the inhibitory effect of tamoxifen on growth of estrogen-dependent human breast cancer (MCF-7) cells implanted in athymic mice. Cancer Res 62, 2474-2477, 2002.
22. Allred DC, Harvey JM, Berardo M, and Clark GM: Prognostic and predictive factors in breast cancer by immunohistochemical analysis. Mod Pathol 11, 155-168, 1998.
23. Mueller SO, Simon S, Chae K, Metzler M, and Korach KS: Phytoestrogens and their human metabolites show distinct agonistic and antagonistic properties on estrogen receptor alpha (ER α) and ER β in human cells. Toxicol Sci 80, 14-25, 2004.
24. Saarinen N, Makela S, and Santti R: Mechanism of anticancer effects of lignans with a special emphasis on breast cancer. In Flaxseed in Human Nutrition (2nd ed.), Thompson LU and Cunnane SC (eds.). Champaign, IL: AOCS Press, 2003, pp 223-231.
25. Evans B, Griffiths K, and Morton M: Inhibition of 5 α-reductase in genital skin fibroblasts and prostate tissue by dietary lignans and isoflavonoids. J Endocrinol 147, 295-302, 1995.
26. Brooks JD and Thompson LU: Mammalian lignans and genistein decrease the activity of aromatase and 17β-hydroxysteroid dehydrogenase in MCF-7 cells. J Steroid Biochem Mol Biol 94, 461-467, 2005.
27. Saarinen NM, Huovinen R, Warri A, Makela SI, Valentin-Blasini L, et al.: Enterolactone inhibits the growth of 7,12-dimethylbenz(a)anthracene-induced mammary carcinomas in the rat. Mol Cancer Ther 1, 869-876, 2002.
28. Limer JL and Speirs V: Phyto-oestrogens and breast cancer chemoprevention. Breast Cancer Res 6, 119-127, 2004.
29. Wang C and Kurzer MS: Phytoestrogen concentration determines effects on DNA synthesis in human breast cancer cells. Nutr Cancer 28, 236-247, 1997.
30. Saarinen NM, Power KA, Chen J, and Thompson LU: Flaxseed attenuates the tumor growth stimulating effect of soy protein in ovariectomized athymic mice with mcf-7 human breast cancer xenografts. Intl J Cancer 119, 925-931, 2006.
31. Power KA, Saarinen NM, Chen JM, and Thompson LU: Mammalian lignans enterolactone and enterodiol, alone and in combination with the isoflavone genistein, do not promote the growth of MCF-7 xenografts in ovariectomized athymic nude mice. Int J Cancer 118, 1316-1320, 2006.
32. Rose DP: Effects of dietary fatty acids on breast and prostate cancers: evidence from in vitro experiments and animal studies. Am J Clin Nutr 66, 1513S-1522S, 1997.
33. Stoll BA: n-3 fatty acids and lipid peroxidation in breast cancer inhibition. Br J Nutr 87, 193-198, 2002.
34. Rose DP: Dietary fatty acids and prevention of hormone-responsive cancer. Proc Soc Exp Biol Med 216, 224-233, 1997.
35. El-Sohemy A and Archer MC: Regulation of mevalonate synthesis in rat mammary glands by dietary n-3 and n-6 polyunsaturated fatty acids. Cancer Res 57, 3685-3687, 1997.
36. DeGraffenried LA, Friedrichs WE, Fulcher L, Fernandes G, Silva JM, et al.: Eicosapentaenoic acid restores tamoxifen sensitivity in breast cancer cells with high Akt activity. Ann Oncol 14, 1051-1056, 2003.
37. Sasano H and Ozaki M: Aromatase expression and its localization in human breast cancer. J Steroid Biochem Mol Biol 61, 293-298, 1997.
38. Neuman E, Ladha MH, Lin N, Upton TM, Miller SJ, et al.: Cyclin D1 stimulation of estrogen receptor transcriptional activity independent of cdk4. Mol Cell Biol 17, 5338-5347, 1997.
39. Nahta R, Iglehart JD, Kempkes B, and Schmidt EV: Rate-limiting effects of cyclin D1 in transformation by ErbB2 predicts synergy between herceptin and flavopiridol. Cancer Res 62, 2267-2271, 2002.
40. Liu MM, Albanese C, Anderson CM, Hilty K, Webb P, et al.: Opposing action of estrogen receptors alpha and beta on cyclin D1 gene expression. J Biol Chem 277, 24353-24360, 2002.
41. Strom A, Hartman J, Foster JS, Kietz S, Wimalasena J, et al.: Estrogen receptor beta inhibits 17beta-estradiol-stimulated proliferation of the breast cancer cell line T47D. Proc Natl Acad Sci USA 101, 1566-1571, 2004.
42. Lindberg MK, Moverare S, Skrtic S, Gao H, Dahlman-Wright K, et al.: Estrogen receptor (ER)-beta reduces ERalpha-regulated gene transcription, supporting a "ying yang" relationship between ERalpha and ERbeta in mice. Mol Endocrinol 17, 203-208, 2003.
43. Rickard SE, Yuan YV, and Thompson LU: Plasma insulin-like growth factor I levels in rats are reduced by dietary supplementation of flaxseed or its lignan secoisolariciresinol diglycoside. Cancer Lett 161, 47-55, 2000.
44. Ring A and Dowsett M: Mechanisms of tamoxifen resistance. Endocr Relat Cancer 11, 643-658, 2004.
45. Shou J, Massarweh S, Osborne CK, Wakeling AE, AH S, et al.: Mechanisms of tamoxifen resistance: increased estrogen receplor-HER2/neu cross-talk in ER/HER2-positive breast cancer. J Natl Cancer Inst 96, 926-935, 2004.
46. Nicholson R I and Gee J M: Oestrogen and growth factor cross-talk and endocrine insensitivity and acquired resistance in breast cancer. Br J Cancer 82, 501-513, 2000.
47. Osborne CK, Bardou V, Hopp TA, Chamness GC, Hilsenbeck SG, et al.: Role of the estrogen receptor coactivator AIB1 (SRC-3) and HER-2/neu in tamoxifen resistance in breast cancer. J Natl Cancer Inst 95, 353-361, 2003.
48. Gee JM, Robertson JF, Gutteridge E, Ellis IO, Pinder SE, et al.: Epidermal growth factor receptor/HER2/insulin-like growth factor receptor signalling and oestrogen receptor activity in clinical breast cancer. Endocr Relat Cancer 12, S99-S111, 2005.
49. Nicholson RI, Hutcheson IR, Britton D, Knowlden JM, Giles M, et al.: Growth factor signalling networks in breast cancer and resistance to endocrine agents: new therapeutic strategies. J Steroid Biochem Mol Biol 93, 257-262, 2005.
50. Hamelers IH and Steenbergh PH: Interactions between estrogen and insulin-like growth factor signaling pathways in human breast tumor cells. Endocr Relat Cancer 10, 331-345, 2003.
51. Daniel P, Gaskell SJ, Bishop H, Campbell C, and Nicholson RI: Determination of tamoxifen and biologically active metabolites in human breast tumours and plasma. Eur J Cancer Clin Oncol 17, 1183-1189, 1981.
52. Kisanga ER, Gjerde J, Guerrieri-Gonzaga A, Pigatto F, Pesci-Feltri A, et al.: Tamoxifen and metabolite concentrations in scrum and breast cancer tissue during three dose regimens in a randomized preoperative trial. Clin Cancer Res 10, 2336-2343, 2004.
53. Kisanga ER, Gjerde J, Schjott J, Mellgren G, and Lien EA: Tamoxifen administration and metabolism in nude mice and nude rats. J Steroid Biochem Mol Biol 84, 361-367, 2003.
54. Robinson SP, Langan-Fahey SM, Johnson DA, and Jordan VC: Metabolites, pharmacodynamics, and pharmacokinetics of tamoxifen in rats and mice compared to the breast cancer patient. Drug Metab Dispos 19, 36-43, 1991.